Freeze on drug price increases won’t effect patients

  • Several pharmaceutical companies have recently said they’ll delay some of their price increases, under pressure from the Trump administration. But hospitals have made no such concessions, even though they make up a much larger share of total health care spending.
  • Pfizer, Novartis, Merck and other drug makers have said they will delay, freeze or roll back price increases on some of their medicines. Experts largely dismissed those pledges as political bandages with little real effect on patients’ pocketbooks.
  • Drug pricing is the political controversy of the moment, but hospitals cost the health care system far more.  Retail drug spending represents 10% of U.S. health care spending, while hospital and doctor services consume about half of spending.

Continue reading

Healthcare is broken

KEY TAKEAWAY:Health care is one of the largest costs for people in retirement.  Fidelity annually estimates what a 65-year old couple, retiring in the current year, will need to cover health care and medical expenses throughout retirement. The 2017 estimate is $275,000, a six percent increase over last year’s estimate of $260,000. Continue reading

American healthcare: no conscience, no empathy

KEY TAKEAWAY:  Vertex received approval for a new two-drug therapy called Orkambi, designed to treat 8,500 cystic fibrosis patients over the age of 12 who have the most common mutation for this disease. Vertex has priced this drug at $259,000 per patient annually and, not surprisingly, many are outraged. One patient said ““It’s egregious, this is more than five times the annual salary of the average American family. How can they in good conscience charge that much? Continue reading